Armo Biosciences Inc (NASDAQ:ARMO) Sellers Rose By 18.7% Their Shorts

May 16, 2018 - By Jack Shaw

Armo Biosciences Inc (NASDAQ:ARMO) recorded an increase of 18.7% in shorted shares. FINRA announced in May ARMO’s total 1.29M shorted shares. Previously was reported up change of 18.7% from 1.09M shares. Previous ARMO’s position will need 4 days to recover. It has 357,900 average volume.

ARMO is reaching $49.85 during the last trading session, after increased 0.04%.ARMO BioSciences, Inc. has 481,956 shares volume, 25.77% up from normal. ARMO is and has moved 0.00% since May 16, 2017. The stock underperformed the S&P 500 by 11.55%.

ARMO BioSciences, Inc., an immuno-oncology company, develops a pipeline of novel product candidates that activate the immune system of cancer patients to recognize and eradicate tumors in the United States.The firm is valued at $1.52 billion. The Company’s lead product candidate is AM0010, a long acting form of human interleukin-10 that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma.Currently it has negative earnings. The firm is also developing AM0010 that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, renal cell carcinoma, colorectal cancer, and melanoma and breast cancer.

For more ARMO BioSciences, Inc. (NASDAQ:ARMO) news announced briefly go to:,,, or The titles are as follows: “Pre-Open Movers 05/10: (ARMO) (HEAR) (VTVT) Higher; (MDCA) (NUAN) (BKNG) Lower (more…)” announced on May 10, 2018, “Benzinga’s Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer’s Trial …” on May 10, 2018, “How this biotech nearly tripled its IPO price with a buyout in less than 4 months” with a publish date: May 10, 2018, “ARMO Biosciences Inc Shares Skyrocket on $1.6 B Eli Lilly Deal” and the last “Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs” with publication date: May 10, 2018.

ARMO BioSciences, Inc. (NASDAQ:ARMO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.